Both industry leaders collectively bring over six decades of experience in building enterprises that have contributed significantly to India’s emergence as the pharmacy of the world. The conversation explored the processes of drug discovery, manufacturing, and commercialization, while underscoring India’s established dominance in generic medicines and the need for stronger innovation-led capabilities.
Rajeev Juneja detailed the origins and growth of Mankind Pharma, founded in 1995 with an initial capital of Rs. 69,000. He explained that the company adopted a differentiated strategy by focusing on underserved regions, including smaller markets in Western Uttar Pradesh, Haryana, and Punjab, while larger pharmaceutical players concentrated on metropolitan areas and major hospitals. Mankind Pharma prioritized deep distribution networks and offered medicines at prices 40 to 60 percent lower than competitors, significantly improving accessibility. The company has since grown into India’s fourth-largest pharmaceutical enterprise, with revenues exceeding Rs. 40,000 crore.
G V Prasad reflected on his association with Dr. Reddy’s Laboratories beginning in 1990, when the organization’s group revenue was under Rs. 100 crore. He described its transformation into a global pharmaceutical enterprise with a business valuation of nearly USD 3 billion, spanning generics, biosimilars, and proprietary drug discovery. He also clarified distinctions between generics, biologics, and innovative medicines, emphasizing India’s strengths as well as its limitations within the global pharmaceutical value chain.
A central focus of the discussion was India’s next growth frontier. While India continues to lead globally in affordable generic drug supply, Prasad noted that significantly higher value creation lies in innovation and the development of new therapies. The dialogue covered emerging segments such as GLP-1 drugs, the economics of drug development, and the capital investment required to build a globally competitive research ecosystem.
The conversation also examined India’s positioning relative to China. Both leaders noted China’s rapid transformation into a pharmaceutical innovation hub, with 29 percent of new cancer drugs now originating from Chinese companies. They emphasized the importance of long-term capital deployment, scientific talent development, research infrastructure, and institutional support to strengthen India’s innovation capacity.
On Active Pharmaceutical Ingredients, the discussion highlighted supply chain resilience and manufacturing competitiveness. G V Prasad stated that India has not lost its API manufacturing capability but has faced economic conditions that shifted production to other regions. Rajeev Juneja added that Indian pharmaceutical companies are increasingly engaging in partnerships and licensing agreements with global innovators to accelerate access to advanced therapies.
The episode also offered insights for young professionals entering the pharmaceutical sector. Both leaders drew from their personal journeys—Rajeev Juneja recalling his early experience as a medical representative and G V Prasad reflecting on building a global enterprise—to highlight opportunities across research, manufacturing, sales, entrepreneurship, and healthcare innovation.
Rajeev Juneja stated, “What you hate becomes your biggest lesson. Going to that pharmacy, sweeping, buying from the wholesale market, I hated it. But that is where I learned how the market really works.”
G V Prasad added, “India is the generic pharmacy of the world. That is a strong foundation. However, the next frontier is discovering new drugs, and the coming decade will be highly significant for Indian pharmaceuticals.”
Nikhil Kamath remarked, “This conversation made clear something I had not fully understood before. By volume, India is the pharmacy of the world, but by revenue, it is barely a rounding error. The real question is how that changes.”
The episode has been released on YouTube as part of the WTF with Nikhil Kamath series, which features long-form, unscripted conversations with leading global figures across business, politics, and technology.
The discussion underscores India’s pivotal position in global healthcare while highlighting the urgent transition required from scale-driven generics to innovation-led pharmaceutical leadership in the coming decade.
About The Author
Comment List